1. Manjunath G, Tighiouart H, Ibrahim H, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community.
J Am Coll Cardiol 2003;41:47–55.
2. Gargiulo R, Suhail F, Lerma EV. Cardiovascular disease and chronic kidney disease.
Dis Mon 2015;61:403–413.
3. Kim SM, Tripathy DR, Park SW, et al. Impact of chronic kidney disease on clinical outcomes in diabetic patients undergoing percutaneous coronary intervention in the era of newer-generation drug-eluting stents.
Korean Circ J 2017;47:222–230.
4. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease.
Kidney Int 2021;99(3S):S1–S87.
5. Cheung AK, Chang TI, Cushman WC, et al. Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: improving Global Outcomes (KDIGO) Controversies Conference.
Kidney Int 2019;95:1027–1036.
6. Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report.
Kidney Int 2011;80:17–28.
7. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States.
JAMA 2007;298:2038–2047.
8. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey.
Am J Kidney Dis 2003;41:1–12.
9. Ku E, Lee BJ, Wei J, Weir MR. Hypertension in CKD: core curriculum 2019.
Am J Kidney Dis 2019;74:120–131.
10. Bie P. Mechanisms of sodium balance: total body sodium, surrogate variables, and renal sodium excretion.
Am J Physiol Regul Integr Comp Physiol 2018;315:R945–R962.
11. Rakova N, Jüttner K, Dahlmann A, et al. Long-term space flight simulation reveals infradian rhythmicity in human Na(+) balance.
Cell Metab 2013;17:125–131.
12. Titze J, Shakibaei M, Schafflhuber M, et al. Glycosaminoglycan polymerization may enable osmotically inactive Na+ storage in the skin.
Am J Physiol Heart Circ Physiol 2004;287:H203–H208.
13. Rossitto G, Mary S, Chen JY, et al. Tissue sodium excess is not hypertonic and reflects extracellular volume expansion.
Nat Commun 2020;11:4222.
14. Oppelaar JJ, Vogt L. Body fluid-independent effects of dietary salt consumption in chronic kidney disease.
Nutrients 2019;11:2779.
15. Rodríguez-Iturbe B, Franco M, Tapia E, Quiroz Y, Johnson RJ. Renal inflammation, autoimmunity and salt-sensitive hypertension.
Clin Exp Pharmacol Physiol 2012;39:96–103.
16. Ozawa Y, Kobori H, Suzaki Y, Navar LG. Sustained renal interstitial macrophage infiltration following chronic angiotensin II infusions.
Am J Physiol Renal Physiol 2007;292:F330–F339.
17. He J, Mills KT, Appel LJ, et al. Urinary sodium and potassium excretion and CKD progression.
J Am Soc Nephrol 2016;27:1202–1212.
18. Mente A, O’Donnell M, Rangarajan S, et al. Urinary sodium excretion, blood pressure, cardiovascular disease, and mortality: a community-level prospective epidemiological cohort study.
Lancet 2018;392:496–506.
19. McMahon EJ, Campbell KL, Bauer JD, Mudge DW. Altered dietary salt intake for people with chronic kidney disease.
Cochrane Database Syst Rev 2015;(2):CD010070.
20. Ekinci EI, Clarke S, Thomas MC, et al. Dietary salt intake and mortality in patients with type 2 diabetes.
Diabetes Care 2011;34:703–709.
21. Mills KT, Chen J, Yang W, et al. Sodium excretion and the risk of cardiovascular disease in patients with chronic kidney disease.
JAMA 2016;315:2200–2210.
22. Hung SC, Lai YS, Kuo KL, Tarng DC. Volume overload and adverse outcomes in chronic kidney disease: clinical observational and animal studies.
J Am Heart Assoc 2015;4:e001918.
23. Borrelli S, Provenzano M, Gagliardi I, et al. Sodium intake and chronic kidney disease.
Int J Mol Sci 2020;21:4744.
24. Guyton AC. Kidneys and fluids in pressure regulation: small volume but large pressure changes.
Hypertension 1992;19(1 Suppl):I2–I8.
25. Titze J, Dahlmann A, Lerchl K, et al. Spooky sodium balance.
Kidney Int 2014;85:759–767.
26. Strauss MB, Lamdin E, Smith WP, Bleifer DJ. Surfeit and deficit of sodium; a kinetic concept of sodium excretion.
AMA Arch Intern Med 1958;102:527–536.
27. Walser M. Phenomenological analysis of renal regulation of sodium and potassium balance.
Kidney Int 1985;27:837–841.
28. Koomans HA, Roos JC, Boer P, Geyskes GG, Mees EJ. Salt sensitivity of blood pressure in chronic renal failure. Evidence for renal control of body fluid distribution in man.
Hypertension 1982;4:190–197.
29. Shibata S, Nagase M, Yoshida S, et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease.
Nat Med 2008;14:1370–1376.
30. Bovée DM, Cuevas CA, Zietse R, Danser AH, Mirabito Colafella KM, Hoorn EJ. Salt-sensitive hypertension in chronic kidney disease: distal tubular mechanisms.
Am J Physiol Renal Physiol 2020;319:F729–F745.
31. Farjah M, Roxas BP, Geenen DL, Danziger RS. Dietary salt regulates renal SGK1 abundance: relevance to salt sensitivity in the Dahl rat.
Hypertension 2003;41:874–878.
32. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease.
Am J Kidney Dis 2004;43(5 Suppl 1):S1–S290.
33. Essig M, Escoubet B, de Zuttere D, et al. Cardiovascular remodelling and extracellular fluid excess in early stages of chronic kidney disease.
Nephrol Dial Transplant 2008;23:239–248.
34. Agarwal R, Pappas MK, Sinha AD. Masked uncontrolled hypertension in CKD.
J Am Soc Nephrol 2016;27:924–932.
35. Drawz PE, Alper AB, Anderson AH, et al. Masked hypertension and elevated nighttime blood pressure in CKD: prevalence and association with target organ damage.
Clin J Am Soc Nephrol 2016;11:642–652.
36. Sinha AD, Agarwal R. The complex relationship between CKD and ambulatory blood pressure patterns.
Adv Chronic Kidney Dis 2015;22:102–107.
37. National Institute for Health and Care Excellence (NICE). Chronic kidney disease in adults: assessment and management [CG182]. London: NICE; 2014.
38. Kario K. Key points of the 2019 Japanese Society of Hypertension Guidelines for the Management of Hypertension.
Korean Circ J 2019;49:1123–1135.
39. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Hypertension 2018;71:e13–e115.
40. You SC, Jung S, Swerdel JN, et al. Comparison of first-line dual combination treatments in hypertension: real-world evidence from multinational heterogeneous cohorts.
Korean Circ J 2020;50:52–68.
41. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension.
Eur Heart J 2018;39:3021–3104.
42. Haider DG, Sauter T, Lindner G, et al. Use of calcium channel blockers is associated with mortality in patients with chronic kidney disease.
Kidney Blood Press Res 2015;40:630–637.
43. Lin YC, Lin JW, Wu MS, Chen KC, Peng CC, Kang YN. Effects of calcium channel blockers comparing to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with hypertension and chronic kidney disease stage 3 to 5 and dialysis: a systematic review and meta-analysis.
PLoS One 2017;12:e0188975.
44. Franco Palacios CR, Goyal P, Thompson AM, Deschaine B. Systolic blood pressure values might further risk-stratify the adverse outcomes of LVH in older patients with chronic kidney disease.
Clin Hypertens 2016;22:21.
45. Zamboli P, De Nicola L, Minutolo R, et al. Effect of furosemide on left ventricular mass in non-dialysis chronic kidney disease patients: a randomized controlled trial.
Nephrol Dial Transplant 2011;26:1575–1583.
46. Vogt L, Waanders F, Boomsma F, de Zeeuw D, Navis G. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan.
J Am Soc Nephrol 2008;19:999–1007.
47. Yang CT, Kor CT, Hsieh YP. Long-term effects of spironolactone on kidney function and hyperkalemia-associated hospitalization in patients with chronic kidney disease.
J Clin Med 2018;7:459.
48. Agarwal R, Rossignol P, Romero A, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial.
Lancet 2019;394:1540–1550.
49. Ellison DH. Clinical pharmacology in diuretic use.
Clin J Am Soc Nephrol 2019;14:1248–1257.
50. He Y, Pachori A, Chen P, et al. Glucosuric, renal and haemodynamic effects of licogliflozin, a dual inhibitor of sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2, in patients with chronic kidney disease: a randomized trial.
Diabetes Obes Metab 2021;23:1182–1190.
51. Kobayashi K, Toyoda M, Hatori N, et al. Sodium-glucose cotransporter 2 inhibitor-induced reduction in the mean arterial pressure improved renal composite outcomes in type 2 diabetes mellitus patients with chronic kidney disease: a propensity score-matched model analysis in Japan.
J Diabetes Investig 2021;12:1408–1416.
52. Rhee JJ, Jardine MJ, Chertow GM, Mahaffey KW. Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY.
Diabetes Obes Metab 2020;22(Suppl 1):46–54.
53. Grodin JL, Tang WH. Sodium-glucose cotransporter-2 inhibitors and loop diuretics for heart failure: priming the natriuretic and metabolic reserve of the kidney.
Circulation 2020;142:1055–1058.
54. Vardeny O, Claggett B, Kachadourian J, et al. Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial.
Eur J Heart Fail 2019;21:337–341.
55. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis.
Lancet 2016;387:957–967.
56. Malhotra R, Nguyen HA, Benavente O, et al. Association between more intensive vs less intensive blood pressure lowering and risk of mortality in chronic kidney disease stages 3 to 5: a systematic review and meta-analysis.
JAMA Intern Med 2017;177:1498–1505.
57. Schmidt M, Mansfield KE, Bhaskaran K, et al. Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: cohort study.
BMJ 2017;356:j791.
58. Hirsch S, Hirsch J, Bhatt U, Rovin BH. Tolerating increases in the serum creatinine following aggressive treatment of chronic kidney disease, hypertension and proteinuria: pre-renal success.
Am J Nephrol 2012;36:430–437.
59. Ruggenenti P, Remuzzi G. Dealing with renin-angiotensin inhibitors, don’t mind serum creatinine.
Am J Nephrol 2012;36:427–429.
60. Hoshida S, Nakagawa T, Shinoda Y, Inui H, Watanabe T. Analysis of the difference in the pressure-natriuresis relationship based on the class of medication using spot urine tests in hypertensive patients.
J Hypertens 2014;3:1000154.
61. Malhotra R, Katz R, Jotwani V, et al. Estimated GFR variability and risk of cardiovascular events and mortality in SPRINT (Systolic Blood Pressure Intervention Trial).
Am J Kidney Dis 2021;78:48–56.
62. Beddhu S, Shen J, Cheung AK, et al. Implications of early decline in eGFR due to intensive BP control for cardiovascular outcomes in SPRINT.
J Am Soc Nephrol 2019;30:1523–1533.
63. Arora N, Katz R, Bansal N. ACE inhibitor/angiotensin receptor blocker use patterns in advanced CKD and risk of kidney failure and death.
Kidney Med 2020;2:248–257.
64. Oh YJ, Kim SM, Shin BC, et al. The impact of renin-angiotensin system blockade on renal outcomes and mortality in pre-dialysis patients with advanced chronic kidney disease.
PLoS One 2017;12:e0170874.
65. Fu EL, Evans M, Clase CM, et al. Stopping renin-angiotensin system inhibitors in patients with advanced CKD and risk of adverse outcomes: a nationwide study.
J Am Soc Nephrol 2021;32:424–435.
66. D’hoore E, Neirynck N, Schepers E, et al. Chronic kidney disease progression is mainly associated with non-recovery of acute kidney injury.
J Nephrol 2015;28:709–716.
67. Chua HR, Wong WK, Ong VH, et al. Extended mortality and chronic kidney disease after septic acute kidney injury.
J Intensive Care Med 2020;35:527–535.
68. Khan YH, Sarriff A, Adnan AS, Khan AH, Mallhi TH. Chronic kidney disease, fluid overload and diuretics: a complicated triangle.
PLoS One 2016;11:e0159335.
69. Velasquez MT, Beddhu S, Nobakht E, Rahman M, Raj DS. Ambulatory blood pressure in chronic kidney disease: ready for prime time?
Kidney Int Rep 2016;1:94–104.
70. Cai W, Lang M, Jiang X, et al. Correlation among high salt intake, blood pressure variability, and target organ damage in patients with essential hypertension: study protocol clinical trial (SPIRIT compliant).
Medicine (Baltimore) 2020;99:e19548.
71. Sarafidis PA, Ruilope LM, Loutradis C, et al. Blood pressure variability increases with advancing chronic kidney disease stage: a cross-sectional analysis of 16 546 hypertensive patients.
J Hypertens 2018;36:1076–1085.
72. Wang Q, Wang Y, Wang J, Zhang L, Zhao MH; C‐STRIDE (Chinese Cohort Study of Chronic Kidney Disease). Short-term systolic blood pressure variability and kidney disease progression in patients with chronic kidney disease: results from C-STRIDE.
J Am Heart Assoc 2020;9:e015359.
73. Chang TI, Tabada GH, Yang J, Tan TC, Go AS. Visit-to-visit variability of blood pressure and death, end-stage renal disease, and cardiovascular events in patients with chronic kidney disease.
J Hypertens 2016;34:244–252.
74. Mallamaci F, Tripepi G, D’Arrigo G, et al. Blood pressure variability, mortality, and cardiovascular outcomes in CKD patients.
Clin J Am Soc Nephrol 2019;14:233–240.
75. Murphy D, Drawz PE. Blood pressure variability in CKD: treatable or hypertension's homocysteine?
Clin J Am Soc Nephrol 2019;14:175–177.
76. Di Iorio B, Pota A, Sirico ML, et al. Blood pressure variability and outcomes in chronic kidney disease.
Nephrol Dial Transplant 2012;27:4404–4410.
77. Gregg LP, Hedayati SS, Yang H, et al. Association of blood pressure variability and diuretics with cardiovascular events in patients with chronic kidney disease stages 1-5.
Hypertension 2021;77:948–959.
78. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
N Engl J Med 2008;359:2417–2428.
79. Perkins RM, Tang X, Bengier AC, Kirchner HL, Bucaloiu ID. Variability in estimated glomerular filtration rate is an independent risk factor for death among patients with stage 3 chronic kidney disease.
Kidney Int 2012;82:1332–1338.
80. Chen SC, Lin MY, Huang TH, et al. Variability in estimated glomerular filtration rate by area under the curve predicts renal outcomes in chronic kidney disease.
ScientificWorldJournal 2014;2014:802037.
81. Sinha AD, Agarwal R. Can chronic volume overload be recognized and prevented in hemodialysis patients?: the pitfalls of the clinical examination in assessing volume status.
Semin Dial 2009;22:480–482.
82. Ekinci C, Karabork M, Siriopol D, Dincer N, Covic A, Kanbay M. Effects of volume overload and current techniques for the assessment of fluid status in patients with renal disease.
Blood Purif 2018;46:34–47.
83. Ok E, Asci G, Chazot C, Ozkahya M, Mees EJ. Controversies and problems of volume control and hypertension in haemodialysis.
Lancet 2016;388:285–293.
84. Kalainy S, Reid R, Jindal K, Pannu N, Braam B. Fluid volume expansion and depletion in hemodialysis patients lack association with clinical parameters.
Can J Kidney Health Dis 2015;2:54.
85. Agarwal R, Weir MR. Dry-weight: a concept revisited in an effort to avoid medication-directed approaches for blood pressure control in hemodialysis patients.
Clin J Am Soc Nephrol 2010;5:1255–1260.
86. McIntyre CW, Salerno FR. Diagnosis and treatment of intradialytic hypotension in maintenance hemodialysis patients.
Clin J Am Soc Nephrol 2018;13:486–489.
87. Flythe JE, Chang TI, Gallagher MP, et al. Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
Kidney Int 2020;97:861–876.
88. Sinha AD, Agarwal R. Clinical pharmacology of antihypertensive therapy for the treatment of hypertension in CKD.
Clin J Am Soc Nephrol 2019;14:757–764.
89. Tieu A, Velenosi TJ, Kucey AS, Weir MA, Urquhart BL. β-Blocker dialyzability in maintenance hemodialysis patients: a randomized clinical trial.
Clin J Am Soc Nephrol 2018;13:604–611.
90. Zoccali C, Moissl U, Chazot C, et al. Chronic fluid overload and mortality in ESRD.
J Am Soc Nephrol 2017;28:2491–2497.
91. Bansal N, McCulloch CE, Lin F, et al. Blood pressure and risk of cardiovascular events in patients on chronic hemodialysis: the CRIC Study (Chronic Renal Insufficiency Cohort).
Hypertension 2017;70:435–443.
92. Shafi T, Sozio SM, Bandeen-Roche KJ, et al. Predialysis systolic BP variability and outcomes in hemodialysis patients.
J Am Soc Nephrol 2014;25:799–809.
93. Charytan D. Is left ventricular hypertrophy a modifiable risk factor in end-stage renal disease.
Curr Opin Nephrol Hypertens 2014;23:578–585.
94. Zoccali C, Benedetto FA, Mallamaci F, et al. Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression.
Kidney Int 2004;65:1492–1498.
95. London GM, Pannier B, Guerin AP, et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study.
J Am Soc Nephrol 2001;12:2759–2767.
96. Donciu MD, Lumita V, Covic A. Chapter 12. Volume overload in ckd: pathophysiology, assessment techniques, consequences and treatment. In: Goldsmith D, Covic A, Spaak J, Cardio-renal clinical challenges. Switzerland: Springer International Publishing, Cham; 2015. p. 119–114.
97. Kayikcioglu M, Tumuklu M, Ozkahya M, et al. The benefit of salt restriction in the treatment of end-stage renal disease by haemodialysis.
Nephrol Dial Transplant 2009;24:956–962.